Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 4

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 4
---
-term persistence in the bloodstream—up to six months—without HLA matching or lymphodepletion. The therapy was well tolerated, with no cases of cytokine release syndrome
(CRS) or GVHD.

These data were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in 2024. Preclinical data from the same program
demonstrated that agenT-797, when combined with bispecific engagers targeting MUC16, HER2, Claudin 18.2, or DLL3, enhanced tumor cell killing, T cell activation, and reduced exhaustion markers—supporting potential future combination strategies.

Further peer-reviewed data support the clinical activity of agenT-797. A case report published in Oncogene in January 2024 described a
patient with metastatic gastric cancer who achieved a 42% tumor reduction and more than nine months of progression-free survival after a single infusion of agenT-797 plus nivolumab. More recently, on July 11, 2025, a landmark Oncogene
publication reported a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer. This patient, who had progressed on multiple prior therapies including chemotherapy, autologous stem cell transplant, and
checkpoint blockade (anti–PD-1, anti–CTLA-4, anti–TIGIT), received a single infusion of agenT-797 with nivolumab. The patient achieved complete

S-1

clinical, radiographic, and biochemical remission, with no evidence of disease more than two years later. Donor iNKT cells were detected in circulation for up to six months, and the regimen was
well tolerated.

Based on these findings, a clinical trial (NCT06251973) is actively enrolling patients with previously treated gastric, esophageal, or
gastroesophageal junction (GEJ) adenocarcinoma. This investigator-sponsored study, led by Dr. Yelena Janjigian at Memorial Sloan Kettering Cancer Center, is evaluating agenT-797 in combination with botensilimab (a novel Fc-enhanced CTLA-4
inhibitor), balstilimab (anti–PD-1), ramucirumab, and paclitaxel. The study, which aims to enroll approximately 38 patients, was highlighted at the ASCO GI Symposium in January 2025 followed by a presentation